Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) was honoured with the “Most Valuable Companies in Hong Kong 2022 Awards” by Mediazone Group, an international business magazine publisher, in recognition of its extensive research and development experience and solid infrastructures. Please refer to the link below for a full media coverage by Mediazone […]
Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, on 26 October 2022, AU409, an investigational new drug candidate, drug product manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited (“Zhaoke Guangzhou”), a wholly-owned subsidiary of the Group, has been approved by the United States Food and Drug Administration (“US FDA”) to […]
Lee’s Pharm has collaborated with Lok Sin Tong Community Pharmacy to donate a total of 900 boxes of masks to support the community. Please contact Lok Sin Tong Community Pharmacy for more details. ดาวน์โหลดไฟล์ ที่มา: Lee’s Pharmaceutical Holdings – News & Media
Recently, the China National Intellectual Property Administration (CNIPA) announced the honours list of “2022 Excellent Enterprise and Role Model Enterprise of China National Intellectual Property”. Having strong innovative capabilities in research and development and well-established intellectual property management system, Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke-Hefei”), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or […]
Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, on September 20, 2022, the marketing authorization for generics of Azilsartan tablets (specification: 20mg), developed and manufactured by the Group, has been obtained from the China National Medical Products Administration (“NMPA”) (國藥准字H20223680). The drug has been approved to treat hypertension. […]
Hong Kong, September 3, 2022, “the Healthcare and Biotech Road Map in Greater Bay Area” Symposium, sponsored by Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), was successfully held both virtually and physically at the center of Hong Kong Management Association. Lee’s Pharm was awarded with the certificate issued by Greater Bay Area […]
Hong Kong, August 12-14, 2022, the Jiangsu Psychiatry Conference 2022, co-organized by the Jiangsu Medical Association and its branch Psychiatric Association, was successfully held in Jiangsu, China. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) kicked off a Satellite Meeting for Trittico®, the New “Excellent” Treatment for Depression, as to facilitate the intellectual […]
Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) has been recognized again as a “Caring Company” by The Hong Kong Council of Social Service (HKCSS). Lee’s Pharm attained Caring Company Award Logo for consecutive two years with good corporate citizenship recognition. ดาวน์โหลดข่าวฉบับเต็ม (PDF) ที่มา: Lee’s Pharmaceutical Holdings – News & Media
LOS ALTOS, Calif., July 18, 2022 — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the Company has entered into an agreement granting exclusive rights to develop, market and commercialize Renazorb® (lanthanum dioxycarbonate) to Lee’s Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee’s […]
The 2022 China Medical and Health Industry Symbiosis Conference, organized by Menet, the healthcare information platform was held in Huzhou, Zhejiang Province, China from 12 to 15 July, 2022. The lists of “Top 100 ranking of Chinese Pharmaceutical Industry”, “Top Brand of Chinese Pharmaceuticals” and “2022 Most Valuable Product in Partnership for Drug Store Chain […]
Thai 
English